Cover Image
Market Research Report

Cystic Fibrosis -deals Analytics Report, 2010 to 2019

Published by GervanoRA Data Services LLP Product code 816256
Published Content info 41 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cystic Fibrosis -deals Analytics Report, 2010 to 2019
Published: March 29, 2019 Content info: 41 Pages
Description

GervanoRA's ‘Cystic Fibrosis Deals Activity Report, 2010-2019’ has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.

GervanoRA has analyzed more than 90 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.

The report through its meticulous analysis on global therapeutic landscape of Cystic Fibrosis deals assists companies in taking future partnering decisions based on competitor's R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.

For a proper understanding, GervanoRA has segmented the report into sections based on:

  • Analytics based on deal type,
  • Analytics based on deal by value,
  • Analytics based on geography
  • Analytics based on deal maker
  • Year-by-year analytics

The report also includes case studies provided for the deals that were prominent and unique among all the deals.

Table of Contents
Product Code: GERPD001

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. OTHER AVAILABLE DEALS ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

3. ANALYTICS BY DEAL TYPE

  • 3.1. CYSTIC FIBROSIS AGREEMENTS
  • 3.2. CYSTIC FIBROSIS COLLABORATIONS
  • 3.3. CYSTIC FIBROSIS MERGERS & ACQUISITIONS
  • 3.4. CYSTIC FIBROSIS FINANCING- GRANT AND FUNDING DEALS
  • 3.5. CYSTIC FIBROSIS LICENSING DEALS
  • 3.6. CYSTIC FIBROSIS ALLIANCE DEAL

4. ANALYTICS BY DEAL VALUE AND GEOGRAPHY

5. ANALYTICS BY ACTIVE PLAYERS

6. ANALYTICS BY ANNUAL FREQUENCY

7. CASE STUDIES- TOP FIVE PROMINENT DEALS

  • DEAL 1: ROYALTY PHARMA ANNOUNCES $3.3 BN ROYALTY TRANSACTION WITH CYSTIC FIBROSIS FOUNDATION THERAPEUTICS
  • DEAL 2: ASTRAZENECA TO SELL SMALL MOLECULE ANTIBIOTICS BUSINESS TO PFIZER
  • DEAL 3: VERTEX AND PARION SCIENCES ESTABLISH COLLABORATION TO DEVELOP EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITORS IN CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES
  • DEAL 4: VERTEX AND MODERNA ESTABLISH EXCLUSIVE COLLABORATION TO DISCOVER AND DEVELOP MRNA THERAPEUTICS FOR CYSTIC FIBROSIS
  • DEAL 5: VERTEX AND CRISPR THERAPEUTICS ESTABLISH COLLABORATION TO USE CRISPR-CAS9 GENE EDITING TECHNOLOGY TO DISCOVER AND DEVELOP NEW TREATMENTS FOR GENETIC DISEASES

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: MAJOR AGREEMENTS IN THE CYSTIC FIBROSIS AREA
  • TABLE 02: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 03: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 04: MAJOR FINANCING DEALS- GRANTS AND FUNDING IN THE CYSTIC FIBROSIS AREA
  • TABLE 05: MAJOR LICENSING DEALS IN THE CYSTIC FIBROSIS AREA
  • TABLE 06: TOP 10 MAJOR DEALS IN THE CYSTIC FIBROSIS AREA RANKED BY DEAL AMOUNT

LIST OF FIGURES

  • FIGURE 01: CYSTIC FIBROSIS DEALS, BY DEAL TYPE
  • FIGURE 02: CYSTIC FIBROSIS DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 03: CYCTIC FIBROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT
  • FIGURE 04: PHARMACEUTICAL COMPANIES INVOLVED IN MORE THAN A SINGLE DEAL IN CF AREA
  • FIGURE 05: NUMBER OF CYSTIC FIBROSIS DEALS, YEAR BY YEAR
  • FIGURE 06: INCREASING AGREEMENT DEALS
Back to Top